The management of patients with inflammatory bowel disease (IBD) presenting with loss of response (LOR) to anti-tumor necrosis factor (TNF) biologics is an increasingly encountered challenge for clinicians caring for these patients. Clinical decisions are complicated by the lack of consistent terminology and diagnostic criteria to define LOR, the myriad of causes that may give rise to symptoms mimicking LOR, and the multiplicity of possible medical interventions. Choosing the best next step is dependent first on accurate identification of the etiology of symptoms and specifically on ascertaining that IBD activity is responsible for the flares. At this point, some patients with mild symptoms may improve without any intervention, so watchful waiting should be borne in mind for these cases, at least for a limited period of time. Otherwise, dose intensification or a switch to another anti-TNF should be contemplated, and the decision may be aided by results of drug/anti-drug antibody levels. A switch to another biologic with a different mode of action should also be considered, as well as less well evidence-based options, which may nevertheless benefit some difficult patients. These include the addition of an immunomodulator to reverse immunogenicity and restore clinical response, retreatment with a previously failed anti-TNF and other experimental interventions. Before any of these is contemplated, the patient's adherence to anti-TNF therapy should be verified as it may contribute to LOR in up to 20% of patients.

Keywords:
Anti-tumor necrosis factor antibodies, Inflammatory bowel disease, Loss of response, Tumor necrosis factor
1.
Gisbert JP, Panes J: Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-767.
2.
Allez M, Karmiris K, Louis E, et al: Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-366.
3.
D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212.
4.
Ben-Horin S, Chowers Y: Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011;33:987-995.
5.
Billioud V, Sandborn WJ, Peyrin-Biroulet L: Loss of response and need for adalimumab dose intensification in Crohn's disease. A systematic review. Am J Gastroenterol 2011;106:674-684.
6.
Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC): Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol 2013;11:826-831.
7.
Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD: Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2013, DOI: 10.1016/j.cgh.2013.06.010.
8.
Hanauer S, Feagan B, Kichtenshtein G; et al: Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet 2002;359:1541-1549.
9.
Colombel JF, Sandborn WJ, Rutgeerts P, et al: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
10.
Sokol H, Seksik P, Carrat F, et al: Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-1368.
11.
van der Valk ME, van Oijen MG, Ammerlaan M, Siersema PD, Oldenburg B: Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators. Gut 2012;61:324-325.
12.
Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Elyakim R, Ben-Horin S: The temporal evolution of anti-drug antibodies in inflammatory bowel disease patients treated with infliximab. Gut 2013, DOI: 10.1136/gutjnl-2013-305259.
13.
Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group: Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011;34:911-922.
14.
Abraham NS, Richardson P, Castillo D, Kane SV: Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:1281-1287.
15.
Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA: The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol 2010;8:655-659.
16.
Siegel CA, Finlayson SR, Sands BE, Tosteson AN: Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51.
17.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, DʼHaens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395.
18.
Sandborn WJ, Colombel JF, Schreiber S, et al: Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011;17:141-151.
19.
Sandborn WJ, Feagan BG, Marano C, et al: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96.e1-109.e1.
20.
Billioud V, Laharie D, Filippi J, et al: Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011;17:152-159.
21.
Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L: Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013;19:1528-1533.
22.
Kopylov U, Mantzaris GJ, Katsanos KH, et al: The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011;33:349-357.
23.
Katz L, Gisbert JP, Manoogian B, et al: Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012;18:2026-2033.
24.
Ben-Bassat O, Hauenstein S, Iacono A, Irwin SP, Singh S, Greenberg GR: Serum adalimumab and immunogenicity in IBD patients after 80 mg biweekly maintenance therapy. Gastroenterology 2013;144(suppl 1):S-771.
25.
Schnitzler F, Fidder H, Ferrante M, et al: Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
26.
Baert F, Glorieus E, Reenaers C, D'Haens G, Peeters H, Franchimont D, Dewit O, Caenepeel P, Louis E, Van Assche G; BIRD (Belgian IBD Research and Development): Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013;7:154-160.
27.
Irving P, Sastrillo M, Duncan J, Anderson S, Sanderson J: Effectiveness of temporary dose increase at recapturing response in patients on maintenance infliximab. Gut 2011;60:A204.
28.
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-838.
29.
Ma C, Panaccione R, Heitman SJ, et al: Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009;30:977-986.
30.
Hanauer SB, Wagner CL, Bala M, et al: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-553.
31.
Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
32.
Ainsworth MA, Bendtzen K, Brynskov J: Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-948.
33.
Maser EA, Villela R, Silverberg MS, Greenberg GR: Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-1254.
34.
Seow CH, Newman A, Irwin SP, et al: Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
35.
Vermeire S, Noman M, Van Assche G, et al: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-1231.
36.
Ben-Horin S, Yavzori M, Katz L, et al: The immunogenic part of infliximab is the F(ab′)2 fragment, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011;60:41-48.
37.
Karmiris K, Paintaud G, Noman M, et al: Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-1640.
38.
West RL, Zelinkova Z, Wolbink GJ, et al: Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122-1126.
39.
Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S: Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-971.
40.
Afif W, Loftus EV, Faubion WA, et al: Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-1139.
41.
Pariente B, Pineton de Chambrun G, Desroches M, et al: Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:1199-1206.
42.
Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM: Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349-358.
43.
Ordás I, Feagan BG, Sandborn WJ: Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-1087.
44.
Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y: Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-447.
45.
Allez M, Vermeire S, Mozziconacci N, et al: The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101.
46.
Ben-Horin S, Mazor Y, Yanai H, et al: The decline of anti-drug antibody titers after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012;35:714-722.
47.
Baert F, Drobne D, Ballet V, Cleynen I, Compernolle G, Rutgeerts PJ, Van Assche GA, Gils A, Vermeire S: Early trough levels and antibodies predict safety and success of restarting infliximab after long drug holiday. Gastroenterology 2011;5(suppl 1):s62.
48.
Kekow J, Mueller-Ladner U, Schulze-Koops H: Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics 2012;6:191-199.
49.
Sandborn WJ, Feagan BG, Rutgeerts P: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.